BioGaia AB (BIOGY)
11.00
0.00 (0.00%)
USD |
OTCM |
Jan 06, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.113B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 17.15% |
| Valuation | |
| PE Ratio | 35.75 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.708 |
| Price to Book Value | 8.919 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.7023 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.24% |
Profile
| BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden. |
| URL | http://www.biogaia.com |
| Investor Relations URL | https://www.biogaia.com/investors/ |
| HQ State/Province | Stockholm |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 12, 2026 |
| Last Earnings Release | Oct. 22, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2025 |
Ratings
Profile
| BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden. |
| URL | http://www.biogaia.com |
| Investor Relations URL | https://www.biogaia.com/investors/ |
| HQ State/Province | Stockholm |
| Sector | |
| Industry | |
| Next Earnings Release | Feb. 12, 2026 |
| Last Earnings Release | Oct. 22, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2025 |